Product Information
OXCARBAZEPINE 300 MG/5 ML SUSP is a generic product labeled by Bionpharma Inc., priced at $0.1102 per ML under NDC 69452012550. Its NADAC has been published 178 times since May 10, 2023.
FDA first approved this application on Nov 4, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/5mL
Manufacturer
Bionpharma Inc.NDC
69452012550
Classification
Generic
Dosage Form
SUSPENSION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
OXCARBAZEPINEApproval Type
Generic (ANDA)
FDA Application
ANDA209652FDA Approved
11/4/2022
TE Code
AB
On Market Since
2/14/2023
Pharmacological Classes
Price Statistics
The NADAC for OXCARBAZEPINE 300 MG/5 ML SUSP has been published 178 times since May 10, 2023, and over the history we have for it it has declined 68.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1102 per ML |
|---|---|
| All-time high | $0.3973 (Oct 11, 2023) |
| All-time low | $0.1102 (Sep 23, 2026) |
| 52-week high | $0.1664 |
| 52-week low | $0.1102 |
| Median price | $0.2243 |
| Average price | $0.2419 |
| Largest weekly change | +66.8% (Jun 19, 2024) |
| Weeks tracked | 178 |
| Tracking since | May 10, 2023 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Bionpharma Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Oxcarbazepine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Anti-epileptic Agent class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of OXCARBAZEPINE 300 MG/5 ML SUSP?
The current National Average Drug Acquisition Cost (NADAC) for OXCARBAZEPINE 300 MG/5 ML SUSP, manufactured by Bionpharma Inc., is $0.1102 per ML (NDC 69452012550), effective Sep 30, 2026.
How has the price of OXCARBAZEPINE 300 MG/5 ML SUSP changed over time?
Over the history we have for it, the NADAC for OXCARBAZEPINE 300 MG/5 ML SUSP has declined 68.8%. It has been tracked across 178 weekly CMS publications since May 10, 2023.
What are the highest and lowest recorded NADAC prices for OXCARBAZEPINE 300 MG/5 ML SUSP?
Since May 10, 2023, the NADAC for OXCARBAZEPINE 300 MG/5 ML SUSP has ranged from a low of $0.1102 (Sep 23, 2026) to a high of $0.3973 (Oct 11, 2023), with a median of $0.2243 per ML.
Are there cheaper alternatives to OXCARBAZEPINE 300 MG/5 ML SUSP?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as OXCARBAZEPINE 300 MG/5 ML SUSP in a comparable dosage form, but none are currently priced below it.
Who manufactures OXCARBAZEPINE 300 MG/5 ML SUSP?
OXCARBAZEPINE 300 MG/5 ML SUSP (NDC 69452012550) is labeled by Bionpharma Inc., and CMS classifies it as a generic product.